Monday, 24 October 202200:00 |  | Conference Chair Title to be Confirmed.
Raymond Schiffelers, Professor of Nanomedicine, University Medical Center Utrecht, Netherlands
|
| 00:00 |  | Conference Chair Extracellular Vesicles and Nanoparticles For Therapy
Dominique PV de Kleijn, Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute, University Medical Center Utrecht, The Netherlands, Netherlands
|
| 00:00 |  | Keynote Presentation EV Therapeutics - Challenges of Clinical Translation
Eva Rohde, Head of Department for Transfusion Medicine, Director of GMP Laboratory, Paracelsus Medical University Salzburg, Austria
|
| 00:00 |  | Keynote Presentation Title to be Confirmed.
Bernd Giebel, Group Leader, Institute for Transfusion Medicine, University Hospital Duisburg-Essen, Germany
|
| 00:00 |  | Keynote Presentation Title to be Confirmed.
Sai Kiang Lim, Research Director, Institute of Medical Biology, A*STAR, Singapore
|
| 00:00 |  | Keynote Presentation Title to be Confirmed.
Mario Gimona, Head of Manufacturing-GMP, CSO of Celericon Therapeutics, Paracelsus Medical University Salzburg, Austria
|
| 00:00 |  | Keynote Presentation Title to be Confirmed.
Samir EL-Andaloussi, Associate Professor, Karolinska Institutet, Sweden
|
| 00:00 | Mesenchymal Stromal Cell-derived Extracellular Vesicles as Therapeutic Tool in Neonatology: The Case of Bronchopulmonary Dysplasia
Maurizio Muraca, Professor, Università degli Studi di Padova, Italy
Extreme premature newborns are a fragile population because of immaturity of various organs, requiring variable stays in the ICU. Bronchopulmonary Dysplasia is the most common respiratory disease in babies, resulting in high mortality and high incidence of long-lasting complications and for which no definite cure exists. Treatment with mesenchymal stromal cells (MSCs) and more recently with MSC-derived extracellular vesicles has provided proof-of-principle in animal models and is now entering the clinical phase. In addition to providing preclinical evidence and to complying with regulatory requirements, the therapeutic approach to this peculiar patient population requires a delicate balance between efficacy and potential risks. |
|
Add to Calendar ▼2022-10-24 00:00:002022-10-25 00:00:00Europe/LondonExtracellular Vesicles and Nanoparticle Therapeutics Europe 2022Extracellular Vesicles and Nanoparticle Therapeutics Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
